Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.

NCT07670338 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT07670338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.
Lead sponsor
Shanghai Chest Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
September 1, 2028
Enrollment
308 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural effusions (mpe)